Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review
In individuals infected with hepatitis B virus (HBV), the loss of hepatitis B surface antigen (HBsAg) is the ultimate therapeutic goal, which defines “functional cure.” For individuals living with human immunodeficiency virus (HIV), functional cure occurs roughly 2 per 100 person-years during potent...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/7/1341 |
| _version_ | 1827686736804708352 |
|---|---|
| author | Anders Boyd Lorenza N. C. Dezanet Karine Lacombe |
| author_facet | Anders Boyd Lorenza N. C. Dezanet Karine Lacombe |
| author_sort | Anders Boyd |
| collection | DOAJ |
| description | In individuals infected with hepatitis B virus (HBV), the loss of hepatitis B surface antigen (HBsAg) is the ultimate therapeutic goal, which defines “functional cure.” For individuals living with human immunodeficiency virus (HIV), functional cure occurs roughly 2 per 100 person-years during potent anti-HBV containing antiretroviral therapy. Although this rate may be higher than expected in treated HBV mono-infected individuals, rates of functional cure widely vary between studies (0.6–10.5 per 100 person-years). Similar to HBV mono-infection, the phase of HBV infection, HBV (sub-)genotypes and hepatitis B “e” Ag-negative variants are associated with functional cure in treated HIV-HBV co-infection. In specifically HIV-HBV co-infected individuals, strong increases in CD4+ T cell counts after treatment initiation have also been linked to functional cure, yet this finding is inconsistent across studies. Several markers directly or indirectly reflecting HBV activity are being developed to predict functional cure, such as quantification of HBsAg, hepatitis B core-related antigen, HBsAg protein composition, anti-hepatitis B core antibodies and interferon-gamma-inducible protein 10. Few have been assessed during treatment in HIV-HBV co-infected individuals and none have been validated to predict functional cure. Novel therapeutics for HBV cure are essential for individuals with HIV-HBV co-infection and need to be separately evaluated in this population. |
| first_indexed | 2024-03-10T09:20:57Z |
| format | Article |
| id | doaj.art-9a37ab07281542da820a88e0a97d380c |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T09:20:57Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-9a37ab07281542da820a88e0a97d380c2023-11-22T05:14:27ZengMDPI AGViruses1999-49152021-07-01137134110.3390/v13071341Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature ReviewAnders Boyd0Lorenza N. C. Dezanet1Karine Lacombe2Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, 1018 WT Amsterdam, The NetherlandsInstitut Pierre Louis d’Épidémiologie et de Santé Publique, INSERM, IPLESP, Sorbonne Université, 75012 Paris, FranceInstitut Pierre Louis d’Épidémiologie et de Santé Publique, INSERM, IPLESP, Sorbonne Université, 75012 Paris, FranceIn individuals infected with hepatitis B virus (HBV), the loss of hepatitis B surface antigen (HBsAg) is the ultimate therapeutic goal, which defines “functional cure.” For individuals living with human immunodeficiency virus (HIV), functional cure occurs roughly 2 per 100 person-years during potent anti-HBV containing antiretroviral therapy. Although this rate may be higher than expected in treated HBV mono-infected individuals, rates of functional cure widely vary between studies (0.6–10.5 per 100 person-years). Similar to HBV mono-infection, the phase of HBV infection, HBV (sub-)genotypes and hepatitis B “e” Ag-negative variants are associated with functional cure in treated HIV-HBV co-infection. In specifically HIV-HBV co-infected individuals, strong increases in CD4+ T cell counts after treatment initiation have also been linked to functional cure, yet this finding is inconsistent across studies. Several markers directly or indirectly reflecting HBV activity are being developed to predict functional cure, such as quantification of HBsAg, hepatitis B core-related antigen, HBsAg protein composition, anti-hepatitis B core antibodies and interferon-gamma-inducible protein 10. Few have been assessed during treatment in HIV-HBV co-infected individuals and none have been validated to predict functional cure. Novel therapeutics for HBV cure are essential for individuals with HIV-HBV co-infection and need to be separately evaluated in this population.https://www.mdpi.com/1999-4915/13/7/1341HBsAg seroclearanceHBsAg seroconversionnucleoside/nucleotide analoguechronic hepatitis Bhuman immunodeficiency virus |
| spellingShingle | Anders Boyd Lorenza N. C. Dezanet Karine Lacombe Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review Viruses HBsAg seroclearance HBsAg seroconversion nucleoside/nucleotide analogue chronic hepatitis B human immunodeficiency virus |
| title | Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review |
| title_full | Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review |
| title_fullStr | Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review |
| title_full_unstemmed | Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review |
| title_short | Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review |
| title_sort | functional cure of hepatitis b virus infection in individuals with hiv coinfection a literature review |
| topic | HBsAg seroclearance HBsAg seroconversion nucleoside/nucleotide analogue chronic hepatitis B human immunodeficiency virus |
| url | https://www.mdpi.com/1999-4915/13/7/1341 |
| work_keys_str_mv | AT andersboyd functionalcureofhepatitisbvirusinfectioninindividualswithhivcoinfectionaliteraturereview AT lorenzancdezanet functionalcureofhepatitisbvirusinfectioninindividualswithhivcoinfectionaliteraturereview AT karinelacombe functionalcureofhepatitisbvirusinfectioninindividualswithhivcoinfectionaliteraturereview |